Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KURA ONCOLOGY, INC.

(KURA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Mixed Premarket Wednesday

11/24/2021 | 09:11am EST


ę MT Newswires 2021
All news about KURA ONCOLOGY, INC.
2021Kura Oncology Initiates Dosing in Phase 1/2 Clinical Trial of Head, Neck Cancer Combo T..
MT
2021Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combinat..
GL
2021Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Co..
CI
2021SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura ..
PR
2021Kura Oncology Reports 56% Overall Response Rate in T-Cell Lymphoma Drug Study
MT
2021Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
AQ
2021Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Ly..
CI
2021Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhib..
GL
2021Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Ra..
MT
2021Health Care Stocks Unable to Return to Positive Ground By Wednesday Close
MT
More news
Analyst Recommendations on KURA ONCOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -134 M - -
Net cash 2021 497 M - -
P/E ratio 2021 -6,73x
Yield 2021 -
Capitalization 908 M 908 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 116
Free-Float 94,3%
Chart KURA ONCOLOGY, INC.
Duration : Period :
Kura Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KURA ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 13,64 $
Average target price 37,57 $
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Troy E. Wilson Chairman, President & Chief Executive Officer
Marc Edward Grasso Chief Financial & Business Officer
Mollie Leoni Vice President-Clinical Development
Stephen Dale Chief Medical Officer
Kathleen Ford Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
KURA ONCOLOGY, INC.-2.57%908
GILEAD SCIENCES, INC.-1.16%90 027
REGENERON PHARMACEUTICALS-2.58%64 327
VERTEX PHARMACEUTICALS6.58%59 510
WUXI APPTEC CO., LTD.-3.88%52 722
BIONTECH SE-23.97%47 338